TVRD
Cara Therapeutics Inc.
NASDAQ · Healthcare
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||
| Revenue | 7.1M | 21.0M | 41.9M | 23.0M | 135.1M | 19.9M | 13.5M | 911,000 | 86,000 | 3.8M | 3.2M | 12.0M | 1.2M |
| Cost of Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses | |||||||||||||
| R&D Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total Op. Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income | -28.1M | -121.5M | -87.5M | -89.1M | 5.4M | -111.7M | -77.4M | -59.5M | -58.4M | -25.2M | -18.1M | -237,000 | -6.2M |
| EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Below the Line | |||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Pre-Tax Income | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Income Tax | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | -29.4M | -118.5M | -85.5M | -88.4M | 8.4M | -106.4M | -74.0M | -58.1M | -57.3M | -24.7M | -17.7M | -4.0M | -6.3M |
| Per Share | |||||||||||||
| EPS (basic) | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Shares | |||||||||||||
| Basic Shares | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted Shares | 3M | 5M | 4M | 51M | 48M | 43M | 36M | 31M | 27M | 25M | 21M | 4M | 3M |